|
1
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xu J, Kim TW, Shen L, Sriuranpong V, Pan
H, Xu R, Guo W, Han SW, Liu T, Park YS, et al: Results of a
randomized, double-blind, placebo-controlled, phase III trial of
trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with
previously treated metastatic colorectal cancer: The TERRA study. J
Clin Oncol. 36:350–358. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pfeiffer P, Yilmaz M, Möller S, Zitnjak D,
Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG and
Qvortrup C: TAS-102 with or without bevacizumab in patients with
chemorefractory metastatic colorectal cancer: An
investigator-initiated, open-label, randomised, phase 2 trial.
Lancet Oncol. 21:412–420. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kimura M, Usami E, Iwai M, Teramachi H and
Yoshimura T: Severe neutropenia: A prognosticator in patients with
advanced/recurrent colorectal cancer under oral
trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie. 72:49–52.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nose Y, Kagawa Y, Hata T, Mori R, Kawai K,
Naito A, Sakamoto T, Murakami K, Katsura Y, Ohmura Y, et al:
Neutropenia is an indicator of outcomes in metastatic colorectal
cancer patients treated with FTD/TPI plus bevacizumab: A
retrospective study. Cancer Chemother Pharmacol. 86:427–433.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kasi PM, Kotani D, Cecchini M, Shitara K,
Ohtsu A, Ramanathan RK, Hochster HS, Grothey A and Yoshino T:
Chemotherapy induced neutropenia at 1-month mark is a predictor of
overall survival in patients receiving TAS-102 for refractory
metastatic colorectal cancer: A cohort study. BMC Cancer.
16(467)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kamiimabeppu D, Osumi H, Shinozaki E, Ooki
A, Wakatsuki T, Yoshino K, Sato T, Nakayama I, Ogura M, Takahari D,
et al: Effect of neutropenia on survival outcomes of patients with
metastatic colorectal cancer receiving trifluridine/tipiracil plus
bevacizumab. Oncol Lett. 22(783)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
US Department Of Health And Human
Services: Common terminology criteria for adverse events (CTCAE)
version 5.0. United States, National Cancer Institute, 2017.
(https://ctep.Cancer.Gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdf).
|
|
9
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ikagawa M, Kimura M, Iwai M, Usami E,
Yoshimura T and Yasuda K: Neutropenia as a prognostic factor and
safety of second-line therapy with S-1 for advanced or recurrent
pancreatic cancer. Mol Clin Oncol. 5:283–288. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kimura K, Usami E and Yoshimura T:
Association between severe neutropenia and progression-free
survival in patients with advanced or recurrent breast cancer
treated with Palbociclib. Pharmazie. 75:662–665. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Watanabe D, Fujii H, Ohata K, Iihara H,
Makiyama A, Kobayashi R, Hirose C, Hishida S, Matsuoka S, Tajima
JY, et al: Prognostic impact of severe neutropenia in colorectal
cancer patients treated with TAS-102 and bevacizumab, addressing
immortal-time bias. BMC Cancer. 23(1078)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Domínguez Senín L, Rodriguez Garcés MY,
Aviñó Tarazona V, Amor Urbano M, Santos-Rubio MD and Bayo Calero J:
Analysis of neutropenia as a predictive factor of the efficacy of
trifluridine-tipiracil treatment. Int J Clin Pharmacol Ther.
61:346–353. 2023.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Giuliani J and Bonetti A: The onset of
grade ≥3 neutropenia is associated with longer overall survival in
metastatic colorectal cancer patients treated with
trifluridine/tipiracil. Anticancer Res. 39:3967–3969.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shitara K, Matsuo K, Takahari D, Yokota T,
Inaba Y, Yamaura H, Sato Y, Najima M, Ura T and Muro K:
Neutropaenia as a prognostic factor in metastatic colorectal cancer
patients undergoing chemotherapy with first-line FOLFOX. Eur J
Cancer. 45:1757–1763. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shitara K, Matsuo K, Takahari D, Yokota T,
Shibata T, Ura T, Ito S, Sawaki A, Tajika M, Kawai H and Muro K:
Neutropenia as a prognostic factor in advanced gastric cancer
patients undergoing second-line chemotherapy with weekly
paclitaxel. Ann Oncol. 21:2403–2409. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gurney H: Dose calculation of anticancer
drugs: A review of the current practice and introduction of an
alternative. J Clin Oncol. 14:2590–2611. 1996.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gamelin E, Delva R, Jacob J, Merrouche Y,
Raoul JL, Pezet D, Dorval E, Piot G, Morel A and Boisdron-Celle M:
Individual fluorouracil dose adjustment based on pharmacokinetic
follow-up compared with conventional dosage: Results of a
multicenter randomized trial of patients with metastatic colorectal
cancer. J Clin Oncol. 26:2099–2105. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yoshino T, Cleary JM, Van Cutsem E, Mayer
RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T,
Garcia-Carbonero R, et al: Neutropenia and survival outcomes in
metastatic colorectal cancer patients treated with
trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol.
31:88–95. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yoshino T and Lenz HJ: Reply to the letter
to the editor ‘Neutropenia in metastatic colorectal cancer
receiving trifluridine/tipiracil’ by Colloca et al. Ann
Oncol. 31:1085–1087. 2020.
|
|
21
|
Grothey A, Yoshino T, Bodoky G, Ciuleanu
T, Garcia-Carbonero R, García-Alfonso P, Van Cutsem E, Muro K,
Mytelka DS, Li L, et al: Association of baseline absolute
neutrophil counts and survival in patients with metastatic
colorectal cancer treated with second-line antiangiogenic
therapies: Exploratory analyses of the RAISE trial and validation
in an electronic medical record data set. ESMO Open.
3(e000347)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Carus A, Gurney H, Gebski V, Harnett P,
Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase H and
Donskov F: Impact of baseline and nadir neutrophil index in
non-small cell lung cancer and ovarian cancer patients: Assessment
of chemotherapy for resolution of unfavourable neutrophilia. J
Transl Med. 11(189)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yasue F, Kimura M, Usami E, Iwai M,
Kawachi S, Mitsuoka M, Ikeda Y and Yoshimura T: Risk factors
contributing to the development of neutropenia in patients
receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for
advanced/recurrent colorectal cancer. Pharmazie. 73:178–181.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Saito Y, Takekuma Y, Komatsu Y and
Sugawara M: Impact of renal impairment on early development of
severe neutropenia with trifluridine/tipiracil treatment for
metastatic colorectal cancer. Sci Rep. 14(26990)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gurney H: How to calculate the dose of
chemotherapy. Br J Cancer. 86:1297–1302. 2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Newell DR: Getting the right dose in
cancer chemotherapy-time to stop using surface area? Br J Cancer.
86:1207–1208. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Drami I, Pring ET, Gould L, Malietzis G,
Naghibi M, Athanasiou T, Glynne-Jones R and Jenkins JT: Body
composition and dose-limiting toxicity in colorectal cancer
chemotherapy treatment; a systematic review of the literature.
Could muscle mass be the new body surface area in chemotherapy
dosing? Clin Oncol (R Coll Radiol). 33:e540–e552. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Benson AB, Venook AP, Adam M, Chang G,
Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna
I, et al: Colon Cancer, version 3.2024, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 22 (2
D)(e240029)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kiss I: New ESMO guidelines for clinical
practice in metastatic colorectal cancer-commentary on changes in
systemic therapy. Klin Onkol. 36:473–476. 2023.PubMed/NCBI View Article : Google Scholar
|
